Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
Adverse Effect Profile and Safety The most common adverse effects include gastrointestinal intolerance (nausea, vomiting, diarrhea), transient fatigue, and early satiety
Insurance companies often require: sleep study results documentation of severity Expanded Medicare coverage coming July, 2026
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
JAMA Ophthalmol [Internet]
J Cell Biochem (2008) 105(6):134251
Luck MR, Jeyaseelan I, Scholes RA
US$ 23.10
US$ 23.45
US$ 20.03
US$ 23.80
US$ 29.42
US$ 28.76
US$ 29.93
US$ 29.32
US$ 22.45
US$ 24.31
US$ 23.55
US$ 23.20
